ARTICLE | Top Story
Arca falls on Gencaro complete response
June 2, 2009 2:31 AM UTC
Arca biopharma Inc. (NASDAQ:ABIO) fell $4.16 (45%) to $5.13 on Monday after receiving a complete response from FDA for an NDA for Gencaro bucindolol to treat chronic heart failure. Arca said FDA reque...